Owlet, Inc. (OWLT), headquartered in Lehi, Utah, operates as a pediatric health platform focused on infant and child monitoring. The company is best known for its Dream Sock wearable monitor, which tracks a baby's pulse rate and oxygen levels, and its Dream Duo and Dream Sight camera products. Owlet positions itself as the only company in the world offering U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade monitoring in the home. Since 2012, more than 2.5 million parents have used its products, according to the company.
Beyond hardware, Owlet has been building a recurring-revenue software business through its Owlet360 subscription service and its Owlet OnCall telehealth initiative. I follow OWLT closely because of its regulatory moat, its transition toward subscription revenue, and its expansion into a broader connected pediatric health ecosystem that includes the recently launched Smart Thermometer. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, OWLT declined approximately 35%. The stock traded near $4.41 in mid-October and fell to roughly $2.86 by mid-November. Most of that decline occurred in a single session, when shares dropped about 38% following the company's third-quarter earnings release and outlook withdrawal.
The quarterly picture is even weaker. About three months earlier, OWLT traded near $6.27, meaning the stock has lost more than half its value — roughly 54% — over the last quarter. After peaking around $6.66 in mid-August, the shares trended steadily lower through September and October before the November earnings-driven selloff pushed them to their lowest levels of the period.
The dominant catalyst was Owlet's third-quarter 2026 report on November 13. Revenue came in at $30.4 million, down 4.9% from $32.0 million a year earlier, while net income fell to $1.4 million from $4.2 million. Although reported earnings per share of $0.11 beat consensus estimates, the company withdrew its full-year 2026 outlook, citing anticipated remediation expenses, a fourth-quarter retail sales interruption, retailer returns, and near-term demand uncertainty.
The withdrawal was tied to a safety update: after receiving a safety incident report involving exposed camera cables, Owlet initiated a camera cable guard update and began shipping replacement enclosed cable guard systems free of charge. The near-term costs and expected retail disruption outweighed otherwise encouraging metrics, including record subscription revenue of $3.6 million, a gross margin that expanded to 53.8%, and paying subscribers that grew to more than 142,000. The launch of the FDA-registered Smart Thermometer in early November provided a positive product milestone but was not enough to offset the guidance removal.
The multi-month decline reflects a broader shift in sentiment around near-term growth and profitability. In August, Owlet reported better-than-expected second-quarter results, and shares briefly rallied. However, an August 10 FDA enforcement deadline for vital-signs baby monitors triggered aggressive competitor discounting, which management said pressured third-quarter sales. Amazon subsequently removed non-compliant third-party products, leaving Dream Sock as the only baby monitor on the platform tracking instant vital signs, but the near-term competitive disruption weighed on results.
Investor focus gradually shifted from the company's strengthening subscription economics — Owlet360 subscribers grew 83% year over year — toward concerns about hardware revenue trajectory, retail inventory dynamics, and execution risk. The November withdrawal of full-year guidance, combined with the safety update, crystallized those concerns and accelerated the quarterly downtrend. From what I see, this is important because it highlights how quickly sentiment can shift when guidance is pulled.
Looking ahead, investors will monitor the cost and duration of the camera cable guard safety update and any impact on fourth-quarter sales and retailer relationships. Reinstatement or revision of full-year guidance, along with management's commentary on demand recovery, will be closely watched. The trajectory of Owlet360 subscription growth, the rollout of the Smart Thermometer and Owlet OnCall telehealth features, and the pace of Dream Sock sell-through now that non-compliant competitors have been removed from Amazon are additional key factors. Analyst price targets, macroeconomic conditions affecting consumer spending, and any regulatory developments in pediatric monitoring remain important considerations. I’m watching this closely as these elements could shape the stock’s path in coming quarters.
In my view, one resource that has proven helpful for evaluating stocks like this is Tickeron’s AI Trading Bots. These automated strategies cover thousands of tickers and allow users to review performance across different timeframes and risk levels. I often reference the Trending AI Robots section to see which approaches align with current market conditions before forming a broader view on a name such as OWLT.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
OWLT saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In 71 of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OWLT's RSI Indicator exited the oversold zone, 24 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for OWLT just turned positive on November 02, 2026. Looking at past instances where OWLT's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where OWLT advanced for three days, in 209 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OWLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
OWLT broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OWLT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.847) is normal, around the industry mean (4.142). P/E Ratio (-13.900) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.967) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. OWLT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OWLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices